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Screening for Down Syndrome Using
Nuchal Translucency Thickness and Nasal
Bone Examination at Advanced Maternal
Age in Jakarta: A Preliminary Report
I. Oetama Marsis
Background: Older maternal age leads to increased risk for both the mother and
fetus, particularly if the mother is more than 34 years old. We evaluated a non-
invasive method to screen for Down syndrome at a maternal age of 35 years or
more. We measured nuchal translucency thickness (NT) using a fixed cut-off of
3.0 mm or more with a crown–rump length (CRL) of 50–70 mm and nasal bone
(NB) examination at 11–13+6 weeks of gestation.
Materials and Methods: This prospective study was conducted from January 2001
to January 2003. NT was measured at 11–13+6 weeks of gestation. In addition, the
NB was examined from January 2002 to January 2003. Cases with an NT of at
least 3.0 mm were submitted to TORCH examination (toxoplasma, rubella,
cytomegalovirus, and herpes simplex virus I and II). Genetic amniocentesis was
performed at 16 weeks of gestation. Both antenatal and postnatal management and
observations were carried out.
Results: NT was measured in 175 cases between January 2001 and January 2002.
Combined NT measurement and NB examination was performed in 97 cases between
January 2002 and January 2003. Maternal ages ranged from 35 to 43 years, with
first to fifth gravidity. Of the 175 NT cases, seven had NT of at least 3.0 mm.
The detection rate (DR) for Down syndrome was 71.4% (5/7) and the false-positive
rate (FPR) was 1.2% (2/170). Of the 97 NT plus NB absence cases, four had an
NT of at least 3.0 mm and three had no NB. The combination of maternal age,
NT and NB examination gives a DR for Down syndrome of 87.5% (3/4 paralleled
to 3/3) and an FPR of 1% (1/94).
Conclusion: Screening for Down syndrome can be performed in the clinical
setting by measuring NT (using a fixed cut-off of * 3.0 mm and CRL of
50–70 mm) and NB examination at 11–13+6 weeks of gestation. Abnormal NT with
normal karyotype requires strict antenatal and postnatal observation.
(J Med Ultrasound 2004;12:1–6)
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INTRODUCTION
Over the last few decades, substantial changes in
living and marital patterns have occurred in Indonesia,
particularly in urban areas. For reasons associated
with career and occupation, women in Indonesia
generally marry and become pregnant at a more
advanced age than ever before. The increase in
maternal age results in increased risk for both the
mother and fetus. If maternal age is 35 years or
more, the pregnancy is considered high risk [1].
Many authors indicate that the incidence of
pregnancy and labor complications, such as pre-
eclampsia/eclampsia and postpartum hemorrhage,
is higher in women aged 35 years or more. Similar-
ly, the more advanced the maternal age, the higher
the risk for congenital anomalies, chromosomal
anomalies, and fetal growth abnormalities [2–4].
The incidence of chromosomal anomalies, such
as trisomy 21 (Down syndrome), tends to increase
with advancing maternal age. It is estimated that at
a maternal age of 30 years, one case of Down
syndrome is found in 900 deliveries; at a maternal
age of 35 years, one case is found in 360 deliveries;
at a maternal age of 38 years, one case is found
in 170 deliveries; and at a maternal age of 42 years,
one case is found in 55 deliveries [5].
A number of methods are recognized in diagnos-
ing Down syndrome in pregnancy, such as biochem-
ical examination, biophysical examination (invasive
and non-invasive), and combined biochemical and
biophysical examination.
Genetic chorionic villi sampling, which is per-
formed at 11 weeks of gestation or more, and genet-
ic amniocentesis at 15–16 weeks of gestation are
used in the diagnosis of Down syndrome in pregnant
women aged 35 years or more. However, these
methods are invasive and have some serious
shortcomings, i.e. complications that may threaten
fetal life [6,7].
Non-invasive biophysical examinations used to
screen for Down syndrome include ultrasonographic
measurement of nuchal translucency thickness (NT)
and identification of the presence or absence of the
nasal bone (NB).
At issue was whether the determination of NT
cut-off point, which was established by the Fetal
Medicine Foundation (FMF) for diagnosis of Down
syndrome, could be applied in an Asian population
or Asian ethnic groups [8–10]. Jou et al suggest that
it might be best to use an NT cut-off based on MoM
(Multiple of Median) of the crown–rump length
(CRL) for Asian populations [9]. For this reason,
it is necessary to conduct studies to obtain relevant
NT values [9]. With no database of Asian populations,
Jou et al proposed that a fixed NT cut-off of 2.5
or 3.0 mm could be used with a CRL of 50–69 mm
[9]. To facilitate its application in the clinical setting,
a fixed NT cut-off of 3.0 mm was chosen with a
CRL of 50–70 mm.
Similarly, in identification of the presence or
absence of the NB to screen for Down syndrome,
other factors such as CRL and ethnicity should be
taken into account [11,12].
The objective of this study was to find a non-
invasive method (without complications) to screen
for Down syndrome. We measured NT and looked
for the NB using ultrasonography at 11–13+6 weeks
of gestation using a CRL of 50–70 mm, which was
considered feasible in the clinical setting.
MATERIALS AND METHODS
This preliminary, prospective study was performed
at Budhi Jaya Maternity and Children Hospital, Bun-
da Women Hospital, Tebet General Hospital, and
Christian University General Hospital in Jakarta
between January 2001 and January 2003. Budhi Jaya
Maternity and Children Hospital and Bunda Women
Hospital are the main centers for infertility and
perinatal health care in Jakarta. The criteria for
pregnant women to be included in this preliminary
study were: age 35 years or more, healthy, single
pregnancy, 11–13+6 weeks of gestation, and CRL of
50–70 mm (based on ultrasonographic examination).
Pregnant women who met these criteria underwent
NT measurement (between January 2001 and January
2002) or the combination of NT measurement and
NB examination (from January 2002 to January
2003). One operator with 20 years of experience per-
formed the ultrasonographic examinations; most
examinations were carried out using a transabdomi-
nal probe, while a small number of cases underwent
examination using a transvaginal probe. The machines
used were Apoge 800-ATL (Advance Technology
Laboratories Inc, Bothel, WA, USA), SSD 680-Aloka
(Aloka Co Ltd, Tokyo, Japan), Logic _ 200 GE (GE
Medical Systems, Milwaukee, WI, USA), and
Veluson 730 Pro GE (GE Medical Systems
Kretztechnik GmBH & Co OHG, Zipf, Austria).
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NT was measured in accordance with a number
of requirements established by the FMF: fetus in
sagittal position with spine situated posteriorly; fetus
in neutral position with no hyperextension or flexion;
and NT clearly visible for measurement [13]. To
facilitate NT measurement, a fixed cut-off of at least
3.0 mm and a CRL of 50–70 mm were used.
In NB examination, the fetus should preferably
be facing toward the transducer, the image should
be magnified so that only the head and the upper
thorax are visible on the screen, and the mid-sagittal
view of the fetal profile must be obtained. The angle
between the ultrasound transducer and an imaginary
line passing through the fetal profile should be about
45$ and the probe should be gently tilted from one
side of the fetal nose to the other to demonstrate
three distinct lines. The top line represents the skin
and the bottom one, usually thicker and more
echogenic than the overlying skin, represents the
NB, whereas a third line, almost in continuity with
the skin but at a higher level, represents the tip of
the nose. When the NB appears as a thin line, less
echogenic than the overlying skin, it suggests that
the NB is not yet ossified, and it is, therefore,
classified as being absent.
When the NT was at least 3.0 mm and the NB
was invisible, a serum TORCH (toxoplasma, rubella,
cytomegalovirus, and herpes simplex virus I and II)
examination was performed. Genetic amniocentesis
was carried out in mothers at 16 weeks of gestation.
All cases with an NT of at least 3.0 mm and no
visible NB had strict antenatal observation follow-
up until delivery.
The detection rate (DR) and false-positive rate
(FPR) were calculated to evaluate the results of
screening. The DR was the percentage of persons
with a positive test who had trisomy 21, while the
FPR was the percentage of persons without trisomy
21 who had a positive test. The combined test was
expected to enhance the DR and FPR. The estimated
risk for Down syndrome is indicated in relation to
NT and NT plus NB absence.
RESULTS
From January 2001 to January 2002, 175 pregnant
mothers who met the requirements for the study
underwent NT measurement. Maternal age ranged
from 35 to 43 years (mean, 37.8 years) and mean
gravidity was 3.9. NT showed seven cases with NT
of at least 3.0 mm, of which five turned out to have
trisomy 21 (Fig., Table 1). TORCH examination in
seven of these cases was normal and karyotype was
normal in two cases. Thus, in women aged 35 years
or more, NT measurement had a DR for Down
syndrome of 71.4% (5/7) and an FPR of 1.1% (2/170).
From January 2002 to January 2003, 97 pregnant
mothers who met the requirements for this study
underwent NB examination as well as NT mea-
surement. Maternal age ranged from 35 to 43 years
(mean, 37.6 years) and mean gravidity was
3.7. NT showed four cases with NT of at least
3.0 mm, although only three cases had no NB.
TORCH examination in four cases was normal.
Genetic analysis from four cases with NT of at least
3.0 mm (three cases had no NB) showed three cases
with Down syndrome (Table 1). In women aged at
least 35 years, NT plus NB examination had a DR
of 87.5% (3/4 paralleled to 3/3) and an FPR of 1%
(1/94).
In the three cases with an NT of at least 3.0 mm
and normal karyotype (two cases with 46,XY and
one with 46,XX; between January 2001 and Jan-
uary 2003), pregnancy lasted to term. At 16 weeks
of gestation, fetal echocardiography was normal.
Follow-up fetal echocardiography at 20 weeks of
gestation was also normal. Three babies from three
cases with an NT of at least 3.0 mm and normal
karyotype were delivered normally.
Fig. Fetal Down syndrome with measurement of nuchal
translucency thickness (3.7 mm) at 12 weeks of gestation.
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DISCUSSION
Babies with Down syndrome typically have a small
oval-shaped head, low-set ears, small ear lobes, an
oriental appearance with eyes pointing upward and
outward, absence of or a poorly developed nose
bridge, and a Brushfield spot at the epicanthal folds.
In the past, the life expectancy of Down syndrome
patients was low, approximately 8 years. Children
died from infection and cardiac anomalies and were
at risk for leukemia. With the introduction of anti-
biotics and the rapid advances in cardiac surgery,
Down syndrome patients now have a longer life
expectancy [13].
The more advanced the maternal age, the higher
the prevalence of Down syndrome. This may be
because most Down syndrome karyotypes are caused
by non-disjunction of the autosome chromosome in
myosis during ovum formation.
In the 1990s, screening for Down syndrome was
introduced with a combination of maternal age and
NT measurement at 11–14 weeks of gestation. Most
studies have been conducted in unselected cases,
i.e. women of reproductive age. Studies of Down
syndrome have been performed at research centers
[14,15]. A multicenter study has also been performed
in 43 countries in conjunction with the Multicenter
Project of the FMF [13]. This preliminary study,
conducted in selected cases where the maternal age
was 35 years or more, showed a DR for trisomy
21 of 71.4% (5/7) and an FPR of 1.1% (2/170) using
NT measurement. These results are not very different
from those of previous studies (Table 2) [13–15].
In this preliminary study (2001–2003), three cases
had NT above the threshold but normal karyotype.
In the first case, the mother was 37 years old and
the NT was 3.6 mm; in the second case, the mother
was 39 years old and the NT was 3.4 mm; while
in the third case, the mother was 36 years old and
the NT was 3.5 mm (and NB +). In all cases, there
was strict antenatal observation and the babies were
delivered normally. In contrast, in Souka et al’s
study, only 5.56% of 1,080 live births had fetal
defects, genetic syndromes that required surgical
intervention, or mental abnormality [16]. They
conducted the study in 1,320 singleton pregnancies
at 10–14 weeks of gestation using an NT threshold
of at least 3.5 mm and normal karyotype. Only
81.82% (1,080 pregnancies) resulted in live births;
5.15% (68 pregnancies) ended in spontaneous
abortion or intrauterine fetal death, 1.36% (18
pregnancies) ended in fetal/neonatal death, and
11.67% (154 pregnancies) were terminated.
The FMF Multicenter Project found congenital
anomalies (fetal defect and genetic syndrome) in
3.9% of singleton pregnancies using increased NT
thickness and normal karyotype [13]. The prevalence
of fetal anomalies increased with increasing NT.
Thus, it is recommended that strict antenatal and
postnatal observations be carried out in cases with
NT above the threshold and normal karyotype.
There are a number of ways to enhance the DR
for Down syndrome at 11–14 weeks of gestation,
e.g. combined NT measurement and NB examination.
The NB can be visualized using two-dimensional
ultrasonography at 11–14 weeks of gestation [11].
In 60–70% of trisomy 21 cases, no NB is found.
In addition, NB is not visualized in less than 1%
of fetuses with normal karyotype. Absence of NB
or NB hypoplasia is affected by race/ethnic factors
Table 1. Number of cases with Down syndrome (DS)
Case Maternal age (yr) NT (mm) NT (mm) + NB Estimated DS risk (1/number given) Karyotype
1 39 3.7 – 35 (n = 175) 47,XX,+21
2 43 5.7 – 47,XY,+21
3 37 3.8 – 47,XX,+21
4 40 4.3 – 47,XX,+21
5 42 4.5 – 47,XY,+21
6 36 – 4.7/Absent 32 (n = 97) 47,XY,+21
7 37 – 4.1/Absent 47,XX,+21
8 41 – 5.5/Absent 47,XY,+21
NT = nuchal translucency thickness; NB = nasal bone.
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[11,12].
In the present study, a combination of maternal
age of at least 35 years, NT measurement, and NB
examination gave a DR of 87.5% (3/4 paralleled
to 3/3) and an FPR of 1% (1/94). This was not
significantly different from rates obtained by
Nicolaides, who found a DR of 90% and an FPR
of 5% [12].
It remains to be determined whether NB examina-
tion for Down syndrome screening can be applied
in Asian populations or Asian ethnic groups. In his
study, Prefumo did not find NB in 3.4% of the Asian
ethnic group, 1.9% of the Afro-Caribbean ethnic
group, and 1.7% of the Caucasian ethnic group [17].
For this reason, it is necessary to conduct further
studies on NB that involve Asian populations.
CONCLUSIONS
Screening for Down syndrome can be performed in
a clinical setting by measuring NT (with a fixed cut-
off NT * 3.0 mm and CRL at 50–70 mm) and NB
examination at 11–13+6 weeks of gestation. Cases
with NT above the threshold and normal karyotype
require strict antenatal and postnatal observation.
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